New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
09:37 EDTZBRA, PCYC, ALNY, CENT, MUX, PAY, ONXX, CELG, CAP, ARIA, VSTM, MDR, AFFY, MSIOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Affymax (AFFY) initiated with an Outperform at JMP Securities... Alnylam (ALNY) initiated with an Outperform at JMP Securities... Celgene (CELG) initiated with an Outperform at JMP Securities... DSW (DSW) initiated with a Buy at Sterne Agee... McDermott (MDR) initiated with a Neutral at HSBC... Onyx Pharmaceuticals (ONXX) initiated with an Outperform at JMP Securities... Pharmacyclics (PCYC) initiated with an Outperform at JMP Securities... Verastem (VSTM) initiated with an Outperform at JMP Securities... VeriFone (PAY) initiated with a Hold at Jefferies... sZebra Technologies (ZBRA) initiated with a Market Perform at Wells Fargo... ARIAD (ARIA) initiated with an Outperform at JMP Securities... McEwen Mining (MUX) initiated with a Buy at Stifel Nicolaus... Motorola Solutions (MSI) initiated with an Outperform at Wells Fargo... CAI International (CAP) initiated with an Outperform at Wells Fargo... Central Garden & Pet (CENT) initiated with a Neutral at SunTrust.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 21, 2015
10:01 EDTMDROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:36 EDTCELGCelgene price target raised to $139 from $115 at RW Baird
Baird raised its price target on Celgene to $139 from $115 following last week's guidance from the company. Baird reiterated its Outperform rating on Celgene shares.
08:03 EDTZBRAZebra Technologies' WLAN deployed in NYC subways
Zebra Technologies' wireless local area network technology is being used by the New York City Metropolitan Transportation Authority and Transit Wireless to deliver Wi-Fi connectivity service to the subway system. Transit Wireless is deploying a massive WLAN system in New York City's underground subway stations.
06:40 EDTMDRMcDermott downgraded to Neutral from Buy at UBS
Subscribe for More Information
06:08 EDTALNYAlnylam 4.737M share Secondary priced at $95.00
Subscribe for More Information
January 20, 2015
16:04 EDTVSTMVerastem files to sell $40M in common stock
Subscribe for More Information
08:04 EDTVSTMVerastem receives orphan medicinial product designation from EC for VS-5584
Subscribe for More Information
07:36 EDTARIAARIAD says EC endorses final opinion adopted by CHMP on Iclusig
Subscribe for More Information
07:05 EDTVSTMVerastem doses first patient in Phase 1 VS-5584 trial
Subscribe for More Information
January 16, 2015
13:37 EDTPAYManning & Napier Advisors reports 5.15% passive stake in Verifone
09:11 EDTCELGCelgene says oral Otezla approved by European Commission in 2 indications
Celgene International, a wholly-owned subsidiary of Celgene Corporation, announced that the European Commission has granted marketing authorisation for OTEZLA, the company’s oral selective inhibitor of phosphodiesterase 4, in two therapeutic indications: For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light. Alone or in combination with Disease Modifying Antirheumatic Drugs, for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. The marketing authorization is based on efficacy and safety data from two Phase III programs, ESTEEM AND PALACE, which demonstrate a maintained clinical response among patients with psoriasis and psoriatic arthritis treated with OTEZLA through 52 weeks, across multiple endpoints. The EC decision follows the positive opinion issued by the Committee for Medicinal Products for Human Use in November 2014.12 OTEZLA will be launched in the European Union in the coming months in accordance with local requirements.
07:03 EDTVSTMVerastem announces publication of scientific data for VS-5584 in cancer research
Verastem announced that a paper, titled “PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells,” has been published in Cancer Research, a peer-reviewed journal of the American Association for Cancer Research. The paper discusses results from preclinical research evaluating VS-5584, a highly potent, selective small molecule inhibitor of mTORC1/2 and Class I PI3K kinases, which preferentially targets cancer stem cells in vitro and in vivo. CSCs represent a subpopulation of cancer cells that have tumor-initiating capability, are particularly resistant to chemotherapy and can mediate tumor recurrence both locally and at metastatic sites. The study results demonstrated that VS-5584 is up to 30-fold more potent in inhibiting the proliferation and survival of CSCs compared to non-CSCs in solid tumor cell populations. VS-5584 preferentially diminished CSC levels in multiple mouse xenograft models of human cancer. Similarly, VS-5584 treatment ex vivo preferentially reduced CSCs in surgically resected breast and ovarian patient tumors. In contrast, chemotherapeutics such as paclitaxel, cisplatin and etoposide effectively targeted bulk tumor cells, but enriched CSCs. Mechanistic investigations revealed that knock down of PI3Kα, PI3Kβ or mTOR alone was insufficient to decrease CSCs, while knock down of PI3Kα, PI3Kβ and mTOR together effectively reduced CSCs mimicking the effect of VS-5584. Consistent with CSC ablation, VS-5584 delayed tumor regrowth following chemotherapy in xenograft models of small cell lung cancer. These data help to elucidate the mechanism of VS-5584 targeting CSCs and provide a strong rationale for the clinical development of VS-5584 in combination with chemotherapeutic agents targeting bulk tumor cells to achieve more durable clinical responses in cancer patients.
05:39 EDTVSTMVerastem risk/reward favorable after pullback, says Mizuho
Subscribe for More Information
January 15, 2015
09:15 EDTMUXOn The Fly: Pre-market Movers
Subscribe for More Information
09:09 EDTMUXMcEwen Mining sees FY15 production 96,500 gold oz, 3.12M silver oz
Subscribe for More Information
07:59 EDTONXX, CELGAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
07:45 EDTMUXMcEwen Mining reports Q4 production 27,412 gold oz, 973,417 silver oz
Subscribe for More Information
06:01 EDTMDRMcDermott and GE launch io oil & gas consulting
McDermott (MDR) and GE Oil & Gas (GE) launched io oil & gas consulting, a new independent venture to transform front-end offshore field development. io will consider the full field as one system and have the technical insight to develop every aspect of the front-end solution. McDermott’s investment in io aligns with the company’s strategy to become more client-focused and responsive to operators’ challenges.
05:55 EDTVSTMVerastem has meeting hosted by Philadelphia Securities Association
Luncheon Meeting to be held in Philadelphia at 11:30 am on January 15 hosted by Philadelphia Securities Association.
05:22 EDTMDRGE Oil & Gas, McDermott launch io oil & gas consulting
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use